The development of chronic kidney disease (CKD) is a risk factor not only for the formation of cardiovascular diseases, but also for chronic heart failure (CHF). The article is a literature review on the problem of the use of sodium-glucose cotransporter type 2 inhibitors (NGLT2) in patients with CKD and CHF. The article presents in detail the mechanisms of action of NGL-2 inhibitors in the light of reno- and cardioprotection. In addition to the glucosuric effect of NGLT2 inhibitors, they have a natriuretic and diuretic effect. One of the effects of NGL-2 inhibitors is the ability to lower blood pressure. Another effect of NGLT2-2 inhibitors, explaining their renoprotective effect, is the effect on glomerular filtration.
